Clinical Trials Results - National Cancer Institute

Skip to content

National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -5 of 5 Show results per page	View Search Criteria \| Help With Results


Sort By:	Version:	Format:

Last Modified: 11/20/2008 First Published: 5/23/2003


1.		Phase I/II Study of Interleukin-2 Gene-Modified Tumor Infiltrating Lymphocytes After Cyclophosphamide and Fludarabine in Patients With Metastatic Melanoma (Phase I Closed to Accrual as of 3/29/06)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Completed				18 and over				NCI				NCI-03-C-0162 NCI-5855, 5855, NCT00062036

Last Modified: 1/1/2001 First Published: 7/1/2000


2.		Phase II Randomized Study of Interleukin-2 Gene Versus Methotrexate in Patients With Recurrent or Refractory Advanced Squamous Cell Carcinoma of the Head and Neck (Summary Last Modified 01/2001)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				NCI, Pharmaceutical / Industry				MCC-12051 MCC-IRB-5482, VALENTIS-IL2-2001, NCI-G00-1810, NCT00006033

Last Modified: 12/23/2008


3.		Phase I Study of Interleukin-2 Gene-Modified Autologous or Partially HLA-Matched Allogeneic Neuroblastoma Cells for Refractory or Recurrent Neuroblastoma (Summary Last Modified 06/2002)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Closed				under 21 at diagnosis				NCI				SJCRH-CYGENE SJCRH-CYGNE2, NCI-H96-0005, NCT00002748

Last Modified: 12/24/2008


4.		Phase I Study of Interleukin-2 Gene-Modified Autologous Tumor Cell Vaccine in Advanced Breast Cancer (Summary Last Modified 11/1999)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Closed				18 and over				NCI				DUMC-93122 NCI-H96-1111


5.		Treating High Risk Leukemia With CD40 Ligand & IL-2 Gene Modified Tumor Vaccine.

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Closed				75 and under				Other				H6408 NCT00058799

Select All on One Page

| | | | | | | |

A Service of the National Cancer Institute